Examining the Costs Associated with the Influenza Drug Xofluza
Xofluza (baloxavir marboxil) made headlines in 2018 as the first new influenza antiviral drug approved by the FDA in nearly 20 years. With the capability to shorten flu duration with just a single dose, Xofluza offered renewed hope of reducing influenza symptoms. But its high price tag left many wondering - what factors determine the cost of Xofluza treatment?
Xofluza's Effectiveness Against the Flu
Xofluza sets itself apart from other antiviral medications Tamiflu and Relenza in a few key ways. First, it aims to stop viral replication by inhibiting the cap-dependent endonuclease protein responsible for reproducing the flu virus. It's also the first influenza drug with a new proposed mechanism of action in 20 years.
In clinical trials, Xofluza shortened flu duration by about one day compared to placebo. It was also more effective than placebo at lowering viral shedding - the expulsion of virus particles to others. These results provided the basis for FDA approval.
The Research and Development Behind Xofluza
Xofluza was developed by Japanese firm Shionogi over the course of 10+ years. The long research process focused on analyzing thousands of small molecule compounds before selecting baloxavir marboxil as the best candidate.
Getting through all 3 phases of gold-standard clinical trials required significant investments of time, money, and effort. Ultimately the R&D costs tallied up quickly for Shionogi. Further expenses around obtaining regulatory licensing and gearing up manufacturing added on additional costs.
Xofluza's Pricing Compared to Other Flu Drugs
Xofluza is priced higher than older flu medications Tamiflu and Relenza, largely due to the recency of its approval and proprietary formula. Wholesale pricing breaks down as follows:
- Xofluza: $150 per single dose
- Tamiflu oral suspension: $42 per dose
- Relenza: $130-$160 for 5 doses
This means a full single course of Xofluza costs over 3 times more than Tamiflu. Insurance coverage and coupons can offset some out-of-pocket expenses. But cost constraints still prevent some prescription candidates from accessing Xofluza.
Key Factors Driving Up the Cost of Xofluza
From development to production to profit-seeking, many intersecting reasons help explain the costly price tag attached to Xofluza doses. Here are some of the primary factors:
1. Small Target Patient Population
Xofluza's approved use is for treating acute, uncomplicated influenza virus cases in ages 12 and up. This narrow indication limits the number of candidates eligible for a prescription. Less potential volume makes costs trickle down less across consumers.
2. Limited Drug Competition
Part of pricing a drug high involves capitalizing on lack of competition before generics push market share. As the sole cap-dependent endonuclease inhibitor and newest flu med, Xofluza stands alone in its drug class for now.
3. Recouping Steep R&D Investments
Recovering the considerable cash outlay required to discover and test Xofluza motivates the manufacturer to set prices high initially. These high margins help counterbalance years of no profit throughout development.
4. Expensive Manufacturing Process
Xofluza utilizes proprietary techniques for large-scale production. The complexity involved makes scaling up commercial manufacturing more costly than older flu meds like Tamiflu.
5. Lack of Good Substitutes
Since no perfect substitutes for this first-in-class flu capsule exist yet, the drugmaker can demand higher prices due to lower competition.
The Potential for Xofluza Costs to Decline
While the upfront sticker price of Xofluza causes some sticker shock today, chances are good costs will moderate over time. Here's why:
Approval for More Uses
If Shionogi obtains FDA approval to market Xofluza for additional flu conditions, the larger customer pool spreads out costs better.
Eventual Patent Expiration
When Xofluza's 20-year patent expires, cheaper generic versions can legally copy the formula. This typically slashes prices by over half.
Increasing Sales Volume
If Xofluza captures substantial flu market share down the road, mass production scales better to lower per unit costs.
Price Negotiation
Large pharmacy benefit managers and Medicare/Medicaid may be able to leverage bulk purchasing power over time to negotiate discounts.
While it may take years for significant cost drops, Xofluza will likely follow the typical prescription drug lifecycle of initial high prices followed by declines over time. But for patients needing relief now, affordability barriers persist.
FAQs
Why does a single dose of Xofluza cost over $150?
The manufacturer sets the price high due to substantial research costs, proprietary manufacturing techniques, lack of competitors, and aiming to maximize profit during the drug’s patent protection period before generics arrive.
How much cheaper will Xofluza get over time?
Once patent exclusivity expires (typically after 20 years), cheaper generic versions can legally copy Xofluza’s formula which usually cuts price tags in half or more compared to brand names.
Is Xofluza covered by health insurance plans?
Coverage varies greatly by specific plan. Many insurers do list Xofluza on their formularies, but may require prior authorization or only cover a percentage of the drug’s high costs.
What assistance options are available for affording Xofluza?
Uninsured and underinsured patients can check requirements for patient assistance programs from the manufacturer providing discounted or free Xofluza for qualifying applicants in financial need.
What are cheaper alternatives to Xofluza for the flu?
Older antiviral medications Tamiflu (oseltamivir) and Relenza (zanamivir) can also shorten flu duration for far lower cost, around $42 per dose for Tamiflu. Using generic oseltamivir instead of brand-name Tamiflu can provide additional savings if available.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.
Add Comment